Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Lanreotid kontra placebo før operasjon for å forhindre en kirurgisk komplikasjon kalt en pankreasfistel

4. november 2026 oppdatert av: SWOG Cancer Research Network

En randomisert fase III blindet studie av lanreotid for forebygging av postoperativ bukspyttkjertelfistel

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

PRIMARY OBJECTIVE:

I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm.

SECONDARY OBJECTIVES:

I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed.

II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo.

III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo.

ADDITIONAL OBJECTIVES:

I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo.

II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo.

III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo.

BANKING OBJECTIVE:

I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.

Studietype

Intervensjonell

Registrering (Antatt)

274

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forente stater, 35233
        • Suspendert
        • University of Alabama at Birmingham Cancer Center
      • Daphne, Alabama, Forente stater, 36526
        • Suspendert
        • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
      • Fairhope, Alabama, Forente stater, 36532
        • Suspendert
        • Thomas Hospital
      • Mobile, Alabama, Forente stater, 36607
        • Suspendert
        • Mobile Infirmary Medical Center
      • Saraland, Alabama, Forente stater, 36571
        • Suspendert
        • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
    • Arizona
      • Gilbert, Arizona, Forente stater, 85234
        • Suspendert
        • Banner MD Anderson Cancer Center
    • California
      • Duarte, California, Forente stater, 91010
        • Suspendert
        • City of Hope Comprehensive Cancer Center
      • La Jolla, California, Forente stater, 92093
        • Rekruttering
        • UC San Diego Moores Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Andrew M. Lowy
      • Loma Linda, California, Forente stater, 92357
        • Suspendert
        • Veterans Affairs Loma Linda Healthcare System
      • Los Angeles, California, Forente stater, 90033
        • Suspendert
        • USC / Norris Comprehensive Cancer Center
      • San Diego, California, Forente stater, 92103
        • Suspendert
        • UC San Diego Medical Center - Hillcrest
    • Delaware
      • Newark, Delaware, Forente stater, 19718
        • Suspendert
        • Christiana Care Health System-Christiana Hospital
      • Newark, Delaware, Forente stater, 19713
        • Suspendert
        • Helen F Graham Cancer Center
      • Newark, Delaware, Forente stater, 19713
        • Suspendert
        • Medical Oncology Hematology Consultants PA
      • Wilmington, Delaware, Forente stater, 19801
        • Suspendert
        • Christiana Care Health System-Wilmington Hospital
    • Florida
      • Ruskin, Florida, Forente stater, 33570
        • Suspendert
        • Moffitt Cancer Center at SouthShore
      • Tampa, Florida, Forente stater, 33612
        • Rekruttering
        • Moffitt Cancer Center - McKinley Campus
        • Ta kontakt med:
        • Hovedetterforsker:
          • Andrew J. Sinnamon
      • Tampa, Florida, Forente stater, 33607
        • Suspendert
        • Moffitt Cancer Center-International Plaza
      • Tampa, Florida, Forente stater, 33612
        • Suspendert
        • Moffitt Cancer Center
      • Wesley Chapel, Florida, Forente stater, 33544
        • Suspendert
        • Moffitt Cancer Center at Wesley Chapel
    • Georgia
      • Atlanta, Georgia, Forente stater, 30342
        • Suspendert
        • Emory Saint Joseph's Hospital
      • Atlanta, Georgia, Forente stater, 30308
        • Suspendert
        • Emory University Hospital Midtown
      • Atlanta, Georgia, Forente stater, 30322
        • Suspendert
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, Forente stater, 30303
        • Suspendert
        • Grady Health System
      • Johns Creek, Georgia, Forente stater, 30097
        • Suspendert
        • Emory Johns Creek Hospital
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Rekruttering
        • Northwestern University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Akhil Chawla
      • Chicago, Illinois, Forente stater, 60612
        • Rekruttering
        • University of Illinois
        • Hovedetterforsker:
          • Aslam Ejaz
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 312-355-3046
      • Geneva, Illinois, Forente stater, 60134
        • Suspendert
        • Northwestern Medicine Cancer Center Delnor
      • Oak Brook, Illinois, Forente stater, 60523
        • Suspendert
        • Northwestern Medicine Oak Brook
      • Orland Park, Illinois, Forente stater, 60462
        • Suspendert
        • Northwestern Medicine Orland Park
      • Warrenville, Illinois, Forente stater, 60555
        • Suspendert
        • Northwestern Medicine Cancer Center Warrenville
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Suspendert
        • Indiana University/Melvin and Bren Simon Cancer Center
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40536
        • Rekruttering
        • University of Kentucky/Markey Cancer Center
        • Hovedetterforsker:
          • Michael J. Cavnar
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 859-257-3379
    • Louisiana
      • New Orleans, Louisiana, Forente stater, 70112
        • Suspendert
        • University Medical Center New Orleans
    • Maryland
      • Elkton, Maryland, Forente stater, 21921
        • Suspendert
        • Christiana Care - Union Hospital
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • Suspendert
        • University of Michigan Rogel Cancer Center
      • Battle Creek, Michigan, Forente stater, 49017
        • Suspendert
        • Bronson Battle Creek
      • Grand Rapids, Michigan, Forente stater, 49503
        • Suspendert
        • Trinity Health Grand Rapids Hospital
      • Grand Rapids, Michigan, Forente stater, 49503
        • Suspendert
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
      • Grand Rapids, Michigan, Forente stater, 49503
        • Suspendert
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Muskegon, Michigan, Forente stater, 49444
        • Suspendert
        • Trinity Health Muskegon Hospital
      • Niles, Michigan, Forente stater, 49120
        • Suspendert
        • Corewell Health Lakeland Hospitals - Niles Hospital
      • Norton Shores, Michigan, Forente stater, 49444
        • Suspendert
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Reed City, Michigan, Forente stater, 49677
        • Suspendert
        • Corewell Health Reed City Hospital
      • Saint Joseph, Michigan, Forente stater, 49085
        • Suspendert
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
      • Saint Joseph, Michigan, Forente stater, 49085
        • Suspendert
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
      • Wyoming, Michigan, Forente stater, 49519
        • Suspendert
        • University of Michigan Health - West
    • Minnesota
      • Aitkin, Minnesota, Forente stater, 56431
        • Suspendert
        • Riverwood Healthcare Center
      • Baxter, Minnesota, Forente stater, 56425
        • Suspendert
        • Essentia Health - Baxter Clinic
      • Brainerd, Minnesota, Forente stater, 56401
        • Suspendert
        • Essentia Health Saint Joseph's Medical Center
      • Crosslake, Minnesota, Forente stater, 56442
        • Suspendert
        • Essentia Health - Saint Joseph's Crosslake Clinic
      • Deer River, Minnesota, Forente stater, 56636
        • Suspendert
        • Essentia Health - Deer River Clinic
      • Detroit Lakes, Minnesota, Forente stater, 56501
        • Suspendert
        • Essentia Health Saint Mary's - Detroit Lakes Clinic
      • Duluth, Minnesota, Forente stater, 55805
        • Suspendert
        • Essentia Health Saint Mary's Medical Center
      • Duluth, Minnesota, Forente stater, 55805
        • Suspendert
        • Miller-Dwan Hospital
      • Duluth, Minnesota, Forente stater, 55805
        • Suspendert
        • Essentia Health Cancer Center
      • Ely, Minnesota, Forente stater, 55731
        • Suspendert
        • Essentia Health - Ely Clinic
      • Fosston, Minnesota, Forente stater, 56542
        • Suspendert
        • Essentia Health - Fosston
      • Hibbing, Minnesota, Forente stater, 55746
        • Suspendert
        • Essentia Health Hibbing Clinic
      • International Falls, Minnesota, Forente stater, 56649
        • Suspendert
        • Essentia Health - International Falls Clinic
      • Moose Lake, Minnesota, Forente stater, 55767
        • Suspendert
        • Essentia Health - Moose Lake Clinic
      • Park Rapids, Minnesota, Forente stater, 56470
        • Suspendert
        • Essentia Health - Park Rapids
      • Pequot Lakes, Minnesota, Forente stater, 56472
        • Suspendert
        • Essentia Health - Saint Joseph's Pequot Lakes Clinic
      • Pine River, Minnesota, Forente stater, 56474
        • Suspendert
        • Essentia Health - Saint Joseph's Pine River Clinic
      • Sandstone, Minnesota, Forente stater, 55072
        • Suspendert
        • Essentia Health Sandstone
      • Staples, Minnesota, Forente stater, 56479
        • Suspendert
        • Essentia Health - Saint Joseph's Staples Clinic
      • Virginia, Minnesota, Forente stater, 55792
        • Suspendert
        • Essentia Health Virginia Clinic
    • Missouri
      • Farmington, Missouri, Forente stater, 63640
        • Rekruttering
        • Parkland Health Center - Farmington
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • Sainte Genevieve, Missouri, Forente stater, 63670
        • Rekruttering
        • Sainte Genevieve County Memorial Hospital
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • St Louis, Missouri, Forente stater, 63131
        • Rekruttering
        • Missouri Baptist Medical Center
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • Sullivan, Missouri, Forente stater, 63080
        • Rekruttering
        • Missouri Baptist Sullivan Hospital
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • Sunset Hills, Missouri, Forente stater, 63127
        • Rekruttering
        • BJC Outpatient Center at Sunset Hills
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
    • Nebraska
      • Omaha, Nebraska, Forente stater, 68198
        • Suspendert
        • University of Nebraska Medical Center
    • Nevada
      • Reno, Nevada, Forente stater, 89502
        • Suspendert
        • Renown Regional Medical Center
    • New Jersey
      • Livingston, New Jersey, Forente stater, 07039
        • Suspendert
        • Saint Barnabas Medical Center
      • New Brunswick, New Jersey, Forente stater, 08903
        • Suspendert
        • Rutgers Cancer Institute of New Jersey
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87106
        • Suspendert
        • University of New Mexico Cancer Center
    • New York
      • Rochester, New York, Forente stater, 14642
        • Suspendert
        • University of Rochester
      • Syracuse, New York, Forente stater, 13210
        • Suspendert
        • State University of New York Upstate Medical University
    • North Carolina
      • Charlotte, North Carolina, Forente stater, 28203
        • Suspendert
        • Carolinas Medical Center/Levine Cancer Institute
      • Concord, North Carolina, Forente stater, 28025
        • Suspendert
        • Atrium Health Cabarrus/LCI-Concord
    • North Dakota
      • Fargo, North Dakota, Forente stater, 58103
        • Suspendert
        • Essentia Health Cancer Center-South University Clinic
      • Fargo, North Dakota, Forente stater, 58122
        • Suspendert
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, Forente stater, 58122
        • Suspendert
        • Sanford Broadway Medical Center
      • Jamestown, North Dakota, Forente stater, 58401
        • Suspendert
        • Essentia Health - Jamestown Clinic
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45219
        • Suspendert
        • University of Cincinnati Cancer Center-UC Medical Center
      • Columbus, Ohio, Forente stater, 43210
        • Suspendert
        • Ohio State University Comprehensive Cancer Center
      • West Chester, Ohio, Forente stater, 45069
        • Suspendert
        • University of Cincinnati Cancer Center-West Chester
    • Pennsylvania
      • Allentown, Pennsylvania, Forente stater, 18104
        • Rekruttering
        • Saint Luke's Cancer Center - Allentown
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 610-776-4714
        • Hovedetterforsker:
          • Darius C. Desai
      • Bethlehem, Pennsylvania, Forente stater, 18015
        • Rekruttering
        • Saint Luke's University Hospital-Bethlehem Campus
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 484-503-4151
        • Hovedetterforsker:
          • Darius C. Desai
      • Chadds Ford, Pennsylvania, Forente stater, 19317
        • Suspendert
        • Christiana Care Health System-Concord Health Center
      • Easton, Pennsylvania, Forente stater, 18045
        • Rekruttering
        • Saint Luke's Hospital-Anderson Campus
        • Ta kontakt med:
        • Hovedetterforsker:
          • Darius C. Desai
      • Quakertown, Pennsylvania, Forente stater, 18951
        • Rekruttering
        • Saint Luke's Hospital - Upper Bucks Campus
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 610-776-4714
        • Hovedetterforsker:
          • Darius C. Desai
      • Stroudsburg, Pennsylvania, Forente stater, 18360
        • Rekruttering
        • Saint Luke's Hospital - Monroe Campus
        • Ta kontakt med:
        • Hovedetterforsker:
          • Darius C. Desai
      • Wilkes-Barre, Pennsylvania, Forente stater, 18711
        • Suspendert
        • Geisinger Wyoming Valley/Henry Cancer Center
    • South Dakota
      • Sioux Falls, South Dakota, Forente stater, 57104
        • Suspendert
        • Sanford Cancer Center Oncology Clinic
      • Sioux Falls, South Dakota, Forente stater, 57117-5134
        • Suspendert
        • Sanford USD Medical Center - Sioux Falls
    • Tennessee
      • Knoxville, Tennessee, Forente stater, 37920
        • Suspendert
        • University of Tennessee - Knoxville
      • Memphis, Tennessee, Forente stater, 38120
        • Suspendert
        • Baptist Memorial Hospital and Cancer Center-Memphis
    • Vermont
      • Burlington, Vermont, Forente stater, 05405
        • Suspendert
        • University of Vermont and State Agricultural College
      • Burlington, Vermont, Forente stater, 05401
        • Suspendert
        • University of Vermont Medical Center
    • Virginia
      • Richmond, Virginia, Forente stater, 23235
        • Rekruttering
        • VCU Massey Cancer Center at Stony Point
        • Ta kontakt med:
        • Hovedetterforsker:
          • Leopoldo J. Fernandez
      • Richmond, Virginia, Forente stater, 23298
        • Rekruttering
        • VCU Massey Comprehensive Cancer Center
        • Hovedetterforsker:
          • Leopoldo J. Fernandez
        • Ta kontakt med:
      • Roanoke, Virginia, Forente stater, 24033
        • Suspendert
        • Carilion Roanoke Memorial Hospital
      • Winchester, Virginia, Forente stater, 22601
        • Suspendert
        • Valley Health / Winchester Medical Center
    • Washington
      • Seattle, Washington, Forente stater, 98195
        • Suspendert
        • University of Washington Medical Center - Montlake
      • Seattle, Washington, Forente stater, 98109
        • Suspendert
        • Fred Hutchinson Cancer Center
    • Wisconsin
      • Ashland, Wisconsin, Forente stater, 54806
        • Suspendert
        • Northwest Wisconsin Cancer Center
      • Ashland, Wisconsin, Forente stater, 54806
        • Suspendert
        • Duluth Clinic Ashland
      • Hayward, Wisconsin, Forente stater, 54843
        • Suspendert
        • Essentia Health-Hayward Clinic
      • Hayward, Wisconsin, Forente stater, 54843
        • Suspendert
        • Tamarack Health Hayward Medical Center
      • Marshfield, Wisconsin, Forente stater, 54449
      • Mukwonago, Wisconsin, Forente stater, 53149
        • Suspendert
        • ProHealth D N Greenwald Center
      • Oconomowoc, Wisconsin, Forente stater, 53066
        • Suspendert
        • ProHealth Oconomowoc Memorial Hospital
      • Spooner, Wisconsin, Forente stater, 54801
        • Suspendert
        • Essentia Health-Spooner Clinic
      • Superior, Wisconsin, Forente stater, 54880
        • Suspendert
        • Essentia Health Saint Mary's Hospital - Superior
      • Waukesha, Wisconsin, Forente stater, 53188
        • Suspendert
        • ProHealth Waukesha Memorial Hospital
      • Waukesha, Wisconsin, Forente stater, 53188
        • Suspendert
        • UW Cancer Center at ProHealth Care

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential

  • Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date

  • Participants must not have a known history of a prior diagnosis of malabsorption syndrome

  • Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization

  • Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization

  • Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization

  • Participants must be ≥ 18 years old

  • Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization

  • Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization

  • Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:

    • Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed
    • Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels
    • Bromocriptine: Dose adjustments may be considered to account for absorption changes
    • Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary
    • CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure
  • In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy

    • NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible
  • In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation

  • Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase [AST] > 190 U/L or alanine aminotransferase [ALT] > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable

  • Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)

  • Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

  • Participants must be offered the opportunity to participate in specimen banking

  • Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study

  • NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.

  • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

  • For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm I (lanreotide, distal pancreatectomy)

Patients receive lanreotide SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

Ancillary studies

Undergo blood sample and pancreas fluid collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Undergo distal pancreatectomy

Given SC

Andre navn:
  • Ipstyl
  • Somatulin
  • Angiopeptin
  • BIM-23014
  • DC 13116
  • Dermopeptin
  • Somatulina
Placebo komparator: Arm II (saline placebo, distal pancreatectomy)

Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

Ancillary studies

Undergo blood sample and pancreas fluid collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Undergo distal pancreatectomy

Given SC

Andre navn:
  • Natriumklorid 0,9 %
  • Vanlig saltvann
  • ISOTONISK NATRIUMKLORIDLØSNING

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of postoperative pancreatic fistula (POPF)
Tidsramme: Up to 60 days after distal pancreatectomy

POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of biochemical leak (BL)
Tidsramme: Up to 60 days after distal pancreatectomy

BL will be defined by the ISGPS as a peritoneal drain amylase greater than three times the upper limit of the institutional normal serum amylase without an effect on clinical management or duration of hospital stay. BL will only be measured in those who had a peritoneal drain placed. Treatment arm differences will be assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy
Number of post-operation hospital days
Tidsramme: From the time of surgery up to 60 days after distal pancreatectomy

Mean hospital length of stay will be compared according to treatment arm via linear regression model with adjustment for stratification factor.

From the time of surgery up to 60 days after distal pancreatectomy
Change in overall quality of life (QOL)
Tidsramme: At baseline and at 14 and 60 days after surgery

Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Core 30 (C30). Treatment arm differences in EORTC QLQ-C30 changes will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

At baseline and at 14 and 60 days after surgery

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Changes in pancreatic specific QOL
Tidsramme: At baseline and up to 60 days after distal pancreatectomy

Will be assessed using EORTC QLQ- Pancreatic Cancer 26. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

At baseline and up to 60 days after distal pancreatectomy
Change in health-related QOL
Tidsramme: At baseline and up to 60 days after distal pancreatectomy

Will be assessed using the European Quality of Life Five Dimension Five Level scale. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

At baseline and up to 60 days after distal pancreatectomy
Delayed gastric emptying (DGE)
Tidsramme: Up to 60 days after distal pancreatectomy

DGE will be defined by the ISGPS as reinsertion or persistence of a nasogastric tube after postoperative day (POD) 3 or inability to tolerate solid oral intake by POD 7. Treatment arm differences in the proportion of participants with DGE will be assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy
Incidence of grades B/C post-pancreatectomy hemorrhage (PPH)
Tidsramme: Up to 60 days after distal pancreatectomy

PPH will be defined by the ISGPS as postoperative intra- or extra-luminal hemorrhage requiring transfusion of fluid or blood, intensive care unit transfer, therapeutic endoscopy, endovascular embolization, or reoperation. Treatment arm differences in the proportion of participants with PPH will be assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy
Time to initiation of adjuvant chemotherapy
Tidsramme: From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy

Distributions of time from surgery to initiation of adjuvant chemotherapy, among participants with planned adjuvant chemotherapy, in each arm will be estimated via cumulative incidence and compared using the stratified log-rank test.

From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
Incidence of nausea and vomiting
Tidsramme: Up to 60 days after distal pancreatectomy

Proportions of participants with any nausea/vomiting will be compared between treatment arms via Fisher's exact test.

Up to 60 days after distal pancreatectomy

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Jonathan G Sham, SWOG Cancer Research Network

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. mai 2025

Primær fullføring (Antatt)

1. april 2029

Studiet fullført (Antatt)

1. april 2029

Datoer for studieregistrering

Først innsendt

29. januar 2025

Først innsendt som oppfylte QC-kriteriene

29. januar 2025

Først lagt ut (Faktiske)

4. februar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • S2408
  • UG1CA189974 (U.S. NIH-stipend/kontrakt)
  • NCI-2024-08361 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
  • SWOG-S2408 (Annen identifikator: DCP)
  • S2408 (Annen identifikator: SWOG)
  • S2408 (Annen identifikator: CTEP)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .